The anti-arrhythmic effects of perhexiline maleate in patients with ischaemic heart disease.
In a preliminary study which lasted 14 weeks, an anti-anginal preparation, perhexiline maleate (Pexid), was prescribed in a dosage of 200 mg twice a day to 7 patients who were suffering from cardiac arrhythmias associated with ischaemic heart disease. There was a significant reduction in ventricular extrasystoles during the 4th and 8th weeks of the study in 6 of the patients who had multiple ventricular ectopic beats. In 4 of these patients, an effective anti-arrhythmic response was maintained until the end of the study. These findings confirm other studies regarding the efficacy of the preparation in reducing ventricular extrasystoles in patients with cardiac ischaemia.
D001145:Arrhythmias, Cardiac / Q000188:drug therapy* / Q000209:etiology; D001281:Atrial Fibrillation / Q000188:drug therapy; D005117:Cardiac Complexes, Premature / Q000188:drug therapy; D003327:Coronary Disease / Q000150:complications*; D005260:Female; D006352:Heart Ventricles; D006801:Humans; D008297:Male; D008875:Middle Aged; D010480:Perhexiline / Q000627:therapeutic use*; D010880:Piperidines / Q000627:therapeutic use*
D010880:Piperidines; D010480:Perhexiline